Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Miromatrix Medical to $6 from $9 and keeps an Overweight rating on the shares post the Q4 results. The company fell short of financial expectations in the quarter, but the main focus remains on the progress of its bioengineered organs, the analyst tells investors in a research note. The firm continues to recommend the shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MIRO:
- Miromatrix Medical reports Q4 EPS (33c) vs. (27c) last year
- Miromatrix Reports Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
- Miromatrix Medical, Inc. (MIRO) Q4 Earnings Cheat Sheet
- Miromatrix to Report Fourth Quarter and Full Year 2022 Financial Results
- MIRO Tanks after Public Offering